Loading...

Sabrina Ronen, PhD

Title(s)Professor, Radiology
SchoolSchool of Medicine
Address1700 4th St
San Francisco CA 94158
Phone415-514-4839
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    International Society of Magnetic Resonance in Medicine (ISMRM)2016Nominated Senior Fellow
    World Molecular Imaging Society2015  - 2018Board of Trustees
    Academy of Radiology Research2013Distinguished Investigator
    International Society of Magnetic Resonance in Medicine (ISMRM)2008  - 2011Annual Meeting Program Committee (AMPC)
    CRUK Institute of Cancer Research1996ICR Fellowship
    Israel Ministry of Science1987Eshkol Scholarship

    Collapse Overview 
    Collapse Overview
    Sabrina M. Ronen, PhD, is a Professor and Director of the Neuroimaging Research Group in the UCSF Department of Radiology and Biomedical Imaging. Dr. Ronen completed her BS in Chemistry and Biochemistry at the Hebrew University in Jerusalem, Israel, received her MS in Chemistry from San Jose State University, and obtained her PhD in Chemical Physics from The Weizmann Institute of Science in Rehovot, Israel. She then trained as a postdoctoral fellow at the Institut Curie in Paris, France, and started her academic career at the Institute of Cancer Research in London, England.

    Dr. Ronen’s Laboratory focuses on developing and mechanistically validating robust non-invasive translatable magnetic resonance (MR)–based biomarkers that can be used to monitor oncogenic transformation and response to therapy. Dr. Ronen has ongoing research projects on monitoring PI3K signaling, detecting the mutational status of isocitrate dehydrogenase, probing the metabolism of brain tumors, and determining the metabolomic profile of pancreatic cancer.

    Expertise:
    Magnetic resonance spectroscopy (MRS), spectroscopic imaging (MRSI), imaging (MRI), metabolism, cancer, bioengineering

    Specialty:
    Preclinical cancer models

    Professional Interests:
    Magnetic resonance, spectroscopy, imaging, cancer, metabolism, cell signaling, biomarkers

    Education and Training:
    • Bachelor of Science: Hebrew University, Jerusalem, Israel - Cum Laude, Chemistry and Biochemistry
    • Masters of Science: San Jose State University, San Jose - Chemistry
    • Doctor of Philosophy: Weizmann Institute of Science, Rehovot, Israel - Chemical Physics
    • Postdoctoral Fellowship: Institut Curie, Paris, France - Imaging
    • Postdoctoral Fellowship: Harefield Hospital, London, England - Imaging

    Collapse Research 
    Collapse Research Activities and Funding
    IMAGING TELOMERE MAINTENANCE MECHANISMS IN GLIOMAS
    NIH R01CA239288Feb 11, 2020 - Jan 31, 2025
    Role: Co-Principal Investigator
    Metabolic Imaging of Brain Tumor Response to Therapy
    NIH R01CA197254Apr 1, 2016 - Mar 31, 2021
    Role: Principal Investigator
    Hyperpolarized arginine imaging of inflammatory cells and their inhibition in GBM
    NIH R21CA201453Dec 1, 2015 - Nov 30, 2018
    Role: Principal Investigator
    Metabolic Reprogramming in Brain Tumors
    NIH R01CA172845Feb 5, 2013 - Feb 28, 2023
    Role: Principal Investigator
    MR Imaging of IDH Mutational Status in Brain Tumors
    NIH R21CA161545Apr 2, 2012 - Mar 31, 2015
    Role: Principal Investigator
    MR Metabolic Imaging of Response to Targeted Therapies in GBM
    NIH R01CA154915Sep 8, 2011 - Jun 30, 2017
    Role: Principal Investigator
    Phosphocholine modulation by oncognenic signaling - MRS studies of mechanism
    NIH R01CA130819Sep 3, 2008 - Jul 31, 2013
    Role: Principal Investigator
    Non-invasive molecular MR spectroscopic imaging of histone deacetylase activity
    NIH R21CA120010Jun 18, 2007 - May 31, 2010
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Non-invasive assessment of telomere maintenance mechanisms in brain tumors. Nat Commun. 2021 01 04; 12(1):92. Viswanath P, Batsios G, Mukherjee J, Gillespie AM, Larson PEZ, Luchman HA, Phillips JJ, Costello JF, Pieper RO, Ronen SM. PMID: 33397920.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    2. Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment. Cancer Res. 2020 11 15; 80(22):5098-5108. Subramani E, Radoul M, Najac C, Batsios G, Molloy AR, Hong D, Gillespie AM, Santos RD, Viswanath P, Costello JF, Pieper RO, Ronen SM. PMID: 32958546.
      View in: PubMed   Mentions:    Fields:    
    3. Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa088. Jones LE, Hilz S, Grimmer MR, Mazor T, Najac C, Mukherjee J, McKinney A, Chow T, Pieper RO, Ronen SM, Chang SM, Phillips JJ, Costello JF. PMID: 32904945.
      View in: PubMed   Mentions:
    4. MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma. Theranostics. 2020; 10(19):8757-8770. PMID: 32754276.
      View in: PubMed   Mentions: 1     Fields:    
    5. In vivo detection of ?-glutamyl-transferase up-regulation in glioma using hyperpolarized ?-glutamyl-[1-13C]glycine. Sci Rep. 2020 04 10; 10(1):6244. Batsios G, Najac C, Cao P, Viswanath P, Subramani E, Saito Y, Gillespie AM, Yoshihara HAI, Larson P, Sando S, Ronen SM. PMID: 32277103.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    6. First hyperpolarized [2-13C]pyruvate MR studies of human brain metabolism. J Magn Reson. 2019 12; 309:106617. Chung BT, Chen HY, Gordon J, Mammoli D, Sriram R, Autry AW, Le Page LM, Chaumeil MM, Shin P, Slater J, Tan CT, Suszczynski C, Chang S, Li Y, Bok RA, Ronen SM, Larson PEZ, Kurhanewicz J, Vigneron DB. PMID: 31648132.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsPHPublic Health
    7. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival. Sci Rep. 2019 07 19; 9(1):10521. Batsios G, Viswanath P, Subramani E, Najac C, Gillespie AM, Santos RD, Molloy AR, Pieper RO, Ronen SM. PMID: 31324855.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    8. In vivo investigation of hyperpolarized [1,3-13C2]acetoacetate as a metabolic probe in normal brain and in glioma. Sci Rep. 2019 03 04; 9(1):3402. Najac C, Radoul M, Le Page LM, Batsios G, Subramani E, Viswanath P, Gillespie AM, Ronen SM. PMID: 30833594.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    9. HDAC inhibition in glioblastoma monitored by hyperpolarized 13 C MRSI. NMR Biomed. 2019 02; 32(2):e4044. Radoul M, Najac C, Viswanath P, Mukherjee J, Kelly M, Gillespie AM, Chaumeil MM, Eriksson P, Delos Santos R, Pieper RO, Ronen SM. PMID: 30561869.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    10. Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology. Neoplasia. 2019 01; 21(1):1-16. Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, Bankson JA, Brindle K, Cunningham CH, Gallagher FA, Keshari KR, Kjaer A, Laustsen C, Mankoff DA, Merritt ME, Nelson SJ, Pauly JM, Lee P, Ronen S, Tyler DJ, Rajan SS, Spielman DM, Wald L, Zhang X, Malloy CR, Rizi R. PMID: 30472500.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimals
    11. Late-stage deuteration of 13C-enriched substrates for T1 prolongation in hyperpolarized 13C MRI. Chem Commun (Camb). 2018 May 17; 54(41):5233-5236. Taglang C, Korenchan DE, von Morze C, Yu J, Najac C, Wang S, Blecha JE, Subramaniam S, Bok R, VanBrocklin HF, Vigneron DB, Ronen SM, Sriram R, Kurhanewicz J, Wilson DM, Flavell RR. PMID: 29726563.
      View in: PubMed   Mentions: 4     Fields:    
    12. Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner. Cancer Metab. 2018; 6:3. Viswanath P, Radoul M, Izquierdo-Garcia JL, Luchman HA, Gregory Cairncross J, Pieper RO, Phillips JJ, Ronen SM. PMID: 29619216.
      View in: PubMed   Mentions:
    13. 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas. Cancer Res. 2018 05 01; 78(9):2290-2304. PMID: 29358170.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    14. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. Proc Natl Acad Sci U S A. 2017 10 03; 114(40):10743-10748. Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Marra MA, Cairncross JG, Perry A, Nelson SJ, Chang SM, Bollen AW, Molinaro AM, Bengtsson H, Olshen AB, Weiss S, Phillips JJ, Luchman HA, Costello JF. PMID: 28916733.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    15. Hyperpolarized 13C MR metabolic imaging can detect neuroinflammation in vivo in a multiple sclerosis murine model. Proc Natl Acad Sci U S A. 2017 08 15; 114(33):E6982-E6991. Guglielmetti C, Najac C, Didonna A, Van der Linden A, Ronen SM, Chaumeil MM. PMID: 28760957.
      View in: PubMed   Mentions: 17     Fields:    Translation:Animals
    16. Autophagy-Dependent Shuttling of TBC1D5 Controls Plasma Membrane Translocation of GLUT1 and Glucose Uptake. Mol Cell. 2017 Jul 06; 67(1):84-95.e5. PMID: 28602638.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    17. Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma. Sci Rep. 2017 03 22; 7:44792. PMID: 28327577.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    18. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance. JCI Insight. 2017 01 26; 2(2):e88815. PMID: 28138554.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    19. Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process. Cancer Res. 2016 11 15; 76(22):6680-6689. PMID: 27758882.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    20. MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy. Top Magn Reson Imaging. 2016 Oct; 25(5):187-196. PMID: 27748711.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    21. Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine. Sci Rep. 2016 08 10; 6:31397. PMID: 27507680.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    22. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis. Mol Cancer Res. 2016 10; 14(10):976-983. PMID: 27430238.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    23. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring. Neuroimage Clin. 2016; 12:180-9. PMID: 27437179.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    24. Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. Oncotarget. 2016 Jun 07; 7(23):34942-55. PMID: 27144334.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    25. Imaging Renal Urea Handling in Rats at Millimeter Resolution using Hyperpolarized Magnetic Resonance Relaxometry. Tomography. 2016 Jun; 2(2):125-135. PMID: 27570835.
      View in: PubMed   Mentions: 9     Fields:    
    26. Accelerated high-bandwidth MR spectroscopic imaging using compressed sensing. Magn Reson Med. 2016 08; 76(2):369-79. PMID: 27228088.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    27. Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells. Front Oncol. 2016; 6:60. PMID: 27014635.
      View in: PubMed   Mentions:
    28. MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival. . 2016 05; 15(5):1113-22. PMID: 26883274.
      View in: PubMed   Mentions:
    29. 1 H-13 C independently tuned radiofrequency surface coil applied for in vivo hyperpolarized MRI. Magn Reson Med. 2016 11; 76(5):1612-1620. PMID: 26597845.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    30. Magnetic Resonance (MR) Metabolic Imaging in Glioma. Brain Pathol. 2015 Nov; 25(6):769-80. PMID: 26526945.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    31. Metabolic reprogramming of pyruvate dehydrogenase is essential for the proliferation of glioma cells expressing mutant IDH1. Mol Cell Oncol. 2016 Apr 01; 3(2):e1077922. PMID: 26985452.
      View in: PubMed   Mentions:
    32. Studies of Metabolism Using (13)C MRS of Hyperpolarized Probes. Methods Enzymol. 2015; 561:1-71. PMID: 26358901.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    33. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. Cancer Res. 2015 Aug 01; 75(15):2999-3009. PMID: 26045167.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    34. Metabolic reprogramming in mutant IDH1 glioma cells. PLoS One. 2015; 10(2):e0118781. PMID: 25706986.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    35. Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. Cancer Res. 2014 Dec 01; 74(23):7115-24. PMID: 25320009.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    36. Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase. PLoS One. 2014; 9(9):e108289. PMID: 25243911.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    37. Rapid in vivo apparent diffusion coefficient mapping of hyperpolarized (13) C metabolites. Magn Reson Med. 2015 Sep; 74(3):622-633. PMID: 25213126.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    38. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed. 2014 Nov; 27(11):1361-70. PMID: 25199993.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    39. Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma. Cancer Res. 2014 Aug 15; 74(16):4247-57. PMID: 24876103.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    40. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell. 2014 May 22; 157(5):1088-103. PMID: 24855946.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansAnimalsCells
    41. MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition. NMR Biomed. 2014 Jun; 27(6):700-8. PMID: 24706368.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    42. Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro Oncol. 2014 May; 16(5):686-95. PMID: 24366912.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    43. Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage. PLoS One. 2013; 8(5):e62351. PMID: 23667469.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    44. HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells. PLoS One. 2013; 8(4):e62610. PMID: 23626839.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    45. Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma. PLoS One. 2013; 8(2):e57610. PMID: 23451252.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    46. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res. 2013 Apr 01; 19(7):1773-83. PMID: 23307858.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansAnimalsCells
    47. Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat Commun. 2013; 4:2429. PMID: 24019001.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    48. Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells. NMR Biomed. 2013 Mar; 26(3):299-306. PMID: 22945392.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    49. Evaluation of heterogeneous metabolic profile in an orthotopic human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging. Magn Reson Med. 2013 Jul; 70(1):33-9. PMID: 22851374.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    50. Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. Neuro Oncol. 2012 Aug; 14(8):1050-61. PMID: 22670012.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    51. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro Oncol. 2012 Mar; 14(3):315-25. PMID: 22156546.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    52. Vascular patterning and permeability in prostate cancer models with differing osteogenic properties. NMR Biomed. 2012 Jun; 25(6):843-51. PMID: 22134886.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    53. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011 Nov 17; 11(12):835-48. PMID: 22089420.
      View in: PubMed   Mentions: 228     Fields:    Translation:HumansAnimalsCells
    54. Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment. PLoS One. 2011; 6(10):e26155. PMID: 22022547.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    55. Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells. NMR Biomed. 2012 Feb; 25(2):379-88. PMID: 22253088.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    56. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. Neuroimage. 2012 Jan 02; 59(1):193-201. Chaumeil MM, Ozawa T, Park I, Scott K, James CD, Nelson SJ, Ronen SM. PMID: 21807103.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimals
    57. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. J Magn Reson Imaging. 2011 Jun; 33(6):1284-90. Park I, Bok R, Ozawa T, Phillips JJ, James CD, Vigneron DB, Ronen SM, Nelson SJ. PMID: 21590996.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansAnimalsCells
    58. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell. 2011 Jan 15; 22(2):165-78. Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM, Debnath J. PMID: 21119005.
      View in: PubMed   Mentions: 190     Fields:    Translation:HumansAnimalsCells
    59. 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2. Breast Cancer Res. 2010; 12(5):R84. Brandes AH, Ward CS, Ronen SM. PMID: 20946630.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    60. Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor. Cancer Res. 2010 Oct 01; 70(19):7400-10. Dafni H, Larson PE, Hu S, Yoshihara HA, Ward CS, Venkatesh HS, Wang C, Zhang X, Vigneron DB, Ronen SM. PMID: 20858719.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    61. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol. 2010 Jun; 12(6):559-69. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK. PMID: 20156803.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimalsCells
    62. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res. 2010 Feb 15; 70(4):1296-305. Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancriekinge M, Dafni H, Sukumar S, Nelson SJ, Vigneron DB, Kurhanewicz J, James CD, Haas-Kogan DA, Ronen SM. PMID: 20145128.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansAnimalsCells
    63. Dynamic nuclear polarization in metabolic imaging of metastasis: common sense, hypersense and compressed sensing. Cancer Biomark. 2010; 7(4):189-99. PMID: 21576812.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    64. Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation. Magn Reson Med. 2008 Oct; 60(4):822-33. Dafni H, Kim SJ, Bankson JA, Sankaranarayanapillai M, Ronen SM. PMID: 18816866.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    65. Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine. . 2008 Aug; 7(8):2556-65. Ross J, Najjar AM, Sankaranarayanapillai M, Tong WP, Kaluarachchi K, Ronen SM. PMID: 18723500.
      View in: PubMed   Mentions:
    66. Monitoring histone deacetylase inhibition in vivo: noninvasive magnetic resonance spectroscopy method. Mol Imaging. 2008 Mar-Apr; 7(2):92-100. Sankaranarayanapillai M, Tong WP, Yuan Q, Bankson JA, Dafni H, Bornmann WG, Soghomonyan S, Pal A, Ramirez MS, Webb D, Kaluarachchi K, Gelovani JG, Ronen SM. PMID: 18706291.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    67. Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. . 2006 May; 5(5):1325-34. Sankaranarayanapillai M, Tong WP, Maxwell DS, Pal A, Pang J, Bornmann WG, Gelovani JG, Ronen SM. PMID: 16731766.
      View in: PubMed   Mentions:
    68. Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. . 2006 Jan; 5(1):187-96. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Eccles SA, Raynaud FI, Workman P, Leach MO, Ronen SM. PMID: 16432178.
      View in: PubMed   Mentions:
    69. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res. 2005 Apr 15; 65(8):3356-63. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Workman P, Leach MO, Ronen SM. PMID: 15833869.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    70. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst. 2003 Nov 05; 95(21):1624-33. Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM. PMID: 14600095.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimals
    71. Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells. Br J Cancer. 2002 Mar 18; 86(6):963-70. Al-Saffar NM, Titley JC, Robertson D, Clarke PA, Jackson LE, Leach MO, Ronen SM. PMID: 11953830.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    72. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer. 2001 Mar 02; 84(5):691-6. Ronen SM, Jackson LE, Beloueche M, Leach MO. PMID: 11237392.
      View in: PubMed   Mentions: 27     Fields:    Translation:AnimalsCells
    73. Imaging biochemistry: applications to breast cancer. Breast Cancer Res. 2001; 3(1):36-40. Ronen SM, Leach MO. PMID: 11250743.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    74. Treatment of SW620 cells with Tomudex and oxaliplatin induces changes in 2-deoxy-D-glucose incorporation associated with modifications in glucose transport. J Nucl Med. 2000 Oct; 41(10):1753-9. Smith TA, Maisey NR, Titley JC, Jackson LE, Leach MO, Ronen SM. PMID: 11038008.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    75. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia. 2000 Jan-Apr; 2(1-2):152-65. Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ, Nalcioglu O, Raghunand N, Ronen SM, Ross BD, Swartz HM. PMID: 10933074.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimals
    76. Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis. Br J Cancer. 1999 Jun; 80(7):1035-41. Ronen SM, DiStefano F, McCoy CL, Robertson D, Smith TA, Al-Saffar NM, Titley J, Cunningham DC, Griffiths JR, Leach MO, Clarke PA. PMID: 10362112.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    77. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed. 1998 Nov; 11(7):314-40. Leach MO, Verrill M, Glaholm J, Smith TA, Collins DJ, Payne GS, Sharp JC, Ronen SM, McCready VR, Powles TJ, Smith IE. PMID: 9859939.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    78. Comparative NMR study of a differentiated rat hepatoma and its dedifferentiated subclone cultured as spheroids and as implanted tumors. NMR Biomed. 1994 Sep; 7(6):278-86. Ronen SM, Volk A, Mispelter J. PMID: 7841024.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    79. The application of 13C NMR to the characterization of phospholipid metabolism in cells. Magn Reson Med. 1992 Jun; 25(2):384-9. Ronen SM, Degani H. PMID: 1319537.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    80. Lipid metabolism in large T47D human breast cancer spheroids: 31P- and 13C-NMR studies of choline and ethanolamine uptake. Biochim Biophys Acta. 1992 Mar 20; 1138(3):203-12. Ronen SM, Rushkin E, Degani H. PMID: 1547282.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    81. Lipid metabolism in T47D human breast cancer cells: 31P and 13C-NMR studies of choline and ethanolamine uptake. Biochim Biophys Acta. 1991 Oct 16; 1095(1):5-16. Ronen SM, Rushkin E, Degani H. PMID: 1657190.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    82. NMR studies of the lipid metabolism of T47D human breast cancer spheroids. FEBS Lett. 1990 Jun 18; 266(1-2):147-9. Ronen SM, Stier A, Degani H. PMID: 2365062.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    83. Studies of the metabolism of human breast cancer spheroids by NMR. Magn Reson Med. 1989 Nov; 12(2):274-81. Ronen S, Degani H. PMID: 2559291.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    Sabrina's Networks
    Concepts (371)
    Derived automatically from this person's publications.
    _
    Co-Authors (54)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _